Xilio Therapeutics, Inc. — Director's Dealing 2021

Oct 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xilio Therapeutics, Inc. (XLO)
CIK: 0001840233
Period of Report: 2021-10-21

Reporting Person: Ross Michael Jay (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-21	Stock Option (right to buy)	$16.00	A	26400	Acquired	2031-10-20	Common Stock (26400)	Direct

Footnotes

F1: The option award was granted on October 21, 2021 and will vest in three equal installments on October 21, 2022, October 21, 2023 and October 21, 2024.